Detailed Abstract
[Liver Poster Presentation 5 - Transplantation]
[P039] Past history of hepatocellular carcinoma increases risk of de novo malignancy after liver transplantation
Yong-Kyu CHUNG, Shin HWANG, Chul-Soo AHN, Deog-Bog MOON, Ki-Hun KIM, Tae-Yong HA, Gi-Won SONG, Dong-Hwan JUNG, Gil-Chun PARK, Sung-Gyu LEE
Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Korea, Korea
Introduction : There is no study on the association between history of hepatocellular carcinoma (HCC) and de novo malignancy after liver transplantation (LT), thus assessed whether HCC can increase risk of posttransplant de novo malignancy.
Methods : We reviewed medical records of adult LT recipients who underwent LT operation between January 2001 and December 2016. After excluding patients who did not survive more than 12 months, 4301 patients were included for analysis.
Results : De novo malignancy developed in 68 patients of 1958 patients without preoperative HCC (3.5%) and 132 patients of 2143 patients with preoperative HCC (6.2%; p=0.0001). Types of de novo malignancies in non-HCC group included stomach cancer (n=15), colorectal cancer (n=10), lung cancer (n=8), skin cancer (n=6), prostate cancer (n=4), breast cancer (n=4), PTLD (n=4), leukemia (n=4), thyroid cancer (n=4), pancreas cancer (n=1), renal cell cancer (n=2), esophageal cancer (n=1), pharyngeal cancer (n=1), submandibular cancer (n=1), MALToma (n=1), tonsil cancer (n=1) and multiple myeloma (n=1). Types of de novo malignancies in HCC group included stomach cancer (n=27), PTLD (n=19), lung cancer (n=18), colorectal cancer (n=15), prostate cancer (n=9), skin cancer (n=7), leukemia (n=4), pancreas cancer (n=4), thyroid cancer (n=4), bladder cancer (n=4), breast cancer (n=4), renal cell cancer (n=3), esophageal cancer (n=3), endometrial cancer (n=3), laryngeal cancer (n=2), sarcoma (n=2), MALToma (n=1), ampullary cancer (n=1), axillary cancer (n=1) and tongue cancer (n=1).
Conclusions : History of HCC indicates higher association of other second malignancies, thus more strict surveillance for HCC recurrence and de novo malignancy is necessary for LT recipients with history of HCC.
Methods : We reviewed medical records of adult LT recipients who underwent LT operation between January 2001 and December 2016. After excluding patients who did not survive more than 12 months, 4301 patients were included for analysis.
Results : De novo malignancy developed in 68 patients of 1958 patients without preoperative HCC (3.5%) and 132 patients of 2143 patients with preoperative HCC (6.2%; p=0.0001). Types of de novo malignancies in non-HCC group included stomach cancer (n=15), colorectal cancer (n=10), lung cancer (n=8), skin cancer (n=6), prostate cancer (n=4), breast cancer (n=4), PTLD (n=4), leukemia (n=4), thyroid cancer (n=4), pancreas cancer (n=1), renal cell cancer (n=2), esophageal cancer (n=1), pharyngeal cancer (n=1), submandibular cancer (n=1), MALToma (n=1), tonsil cancer (n=1) and multiple myeloma (n=1). Types of de novo malignancies in HCC group included stomach cancer (n=27), PTLD (n=19), lung cancer (n=18), colorectal cancer (n=15), prostate cancer (n=9), skin cancer (n=7), leukemia (n=4), pancreas cancer (n=4), thyroid cancer (n=4), bladder cancer (n=4), breast cancer (n=4), renal cell cancer (n=3), esophageal cancer (n=3), endometrial cancer (n=3), laryngeal cancer (n=2), sarcoma (n=2), MALToma (n=1), ampullary cancer (n=1), axillary cancer (n=1) and tongue cancer (n=1).
Conclusions : History of HCC indicates higher association of other second malignancies, thus more strict surveillance for HCC recurrence and de novo malignancy is necessary for LT recipients with history of HCC.
SESSION
Liver Poster Presentation 5
Poster / Exhibition Hall and Lobby(2F) 3/30/2018 2:40 PM - 3:20 PM